In this episode, Ayesha discussed Novo Nordisk’s Ozempic (semaglutide) shortage, largely attributed to off-label prescribing for weight loss and viral TikTok videos. The GLP-1 agonist is indicated as a type 2 diabetes treatment but has weight loss as a side effect. The shortage could give competitor Eli Lilly’s new dual GIP/GLP-1 agonist Mounjaro added market advantage, but can the company meet the unprecedented demand?
Ayesha also talked about Eli Lilly falling victim to a fake Twitter account that tweeted the company was offering free insulin. The fraudulent account has a blue check, which users can purchase through a $8 per month subscription for the revamped Twitter Blue program introduced by Elon Musk. Lilly clarified the fake message, but the tweet has re-ignited debate about the cost of insulin in the US.
Read the full articles here:
Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro
Fraudulent Eli Lilly Twitter Account Announces Free Insulin
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN